Lynn JiangLyvgen Biopharma Shanghai, China;关注立即认领分享关注立即认领分享基本信息浏览量:0职业迁徙个人简介暂无内容研究兴趣论文共 2 篇作者统计合作学者相似作者按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选时间引用量主题期刊级别合作者合作机构Early safety and efficacy from a phase I open-label clinical study of LVGN7409 (CD40 agonist antibody) in patients with advanced or metastatic malignanciesSiqing Fu,Andrae Lavon Vandross, Yi Hsin Hsu,Naiyi Shi,Lynn Jiang,Fusheng Su,Jieyi Wang, C. Hubert ChanJournal of Clinical Oncology(2022)引用1浏览0引用10Early safety and efficacy from a phase I open-label clinical trial of CD137(4-1BB) agonistic antibody LVGN6051 as monotherapy and in combination with pembrolizumabSiqing Fu, Wael A. Harb,Sapna Pradyuman Patel, Charles Lu,Daniel M. Halperin,Yi Hsin Hsu,Naiyi Shi,Yuko Yamamura, Tony Tang,Lynn Jiang,Fusheng Su, Julia Wanda Cohen,JOURNAL OF CLINICAL ONCOLOGY(2021)引用5浏览0引用50作者统计合作学者合作机构D-Core合作者学生导师暂无相似学者,你可以通过学者研究领域进行搜索筛选数据免责声明页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn